Alphavirus replicon particles as immunological adjuvants

US8263092B1 · kind B1 · utility

Assignee

• ALPHAVAX, INC. · US

Inventors

• Jonathan F. Smith · Cary, US
• Bolyn Hubby · Chapel Hill, US
• Peter Lars Aksel Berglund · Seattle, US
• Laura Copp · Raleigh, US
• Whitney Ellis · Oxford, US

Key dates

• Filing date: Sep 12, 2007
• Grant date: Sep 11, 2012
• Expiry date: Feb 10, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/36143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.